Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib pilot study for ischemia-reperfusion injury and allograft pancreatitis in pancreas transplantation
2017-002784-18Phase 2Unknown
- Sponsor
- Clinical Trials and Research Governance
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tofacitinib in ischemia-reperfusion injury (IRI), pancreatitis and Ischemic pancreatitis, sponsored by Clinical Trials and Research Governance. Primary endpoint: C-reactive protein. Status: unknown.
02
Drugs
03
Conditions
ischemia-reperfusion injury (IRI)pancreatitisIschemic pancreatitis
Beyond the preview
Go deeper on 2017-002784-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002784-18.